|Dr. Bernard Gilly Ph.D.||Co-Founder, CEO & Exec. Director||696.01k||N/A||1957|
|Ms. Marie-Claude Holtz||Deputy CEO, Quality VP & Chief Pharmacist||140.1k||N/A||N/A|
|Prof. Jose-Alain Sahel||Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer||N/A||N/A||N/A|
|Prof. Botond Roska||Scientific Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Jean E. Bennett M.D., Ph.D.||Scientific Founder & Vice Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Luk H. Vandenberghe M.D., Ph.D.||Scientific Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Serge Picaud||Scientific Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Prof. Constance L. Cepko||Scientific Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Thomas Gidoin||Chief Financial Officer||N/A||N/A||1983|
|Ms. Marion Ghibaudo||Chief Technical Officer||N/A||N/A||N/A|
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
GenSight Biologics S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.